The latest gastro-intestinal cancer news
ESMO 2022: Cabozantinib plus nivolumab and ipilimumab shows significant PFS benefit for aRCC patients of intermediate or poor risk
“COSMIC-313 is the first metastatic renal cell carcinoma (RCC) phase 3 trial with a doublet…